CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.84B, above the global median of $1.15B
- PositionCurrent ratio is 0.58×, lower than 95% of its Biotechnology peers (median 5.5×)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.47BCHF1.84B · vs all stocks (USD)
Revenue (TTM)
199.71MCHF249.35M · vs all stocks (USD)
Profit Margin
-158.32%vs Biotechnology peers
Beta
1.66xvs all stocks
52-Week Change
106.32%vs all stocks
Market Capitalization
1.47BCHF1.84B · vs all stocks (USD)
Enterprise Value
2.75BCHF3.44B · vs all stocks (USD)
Forward P/E
101.23xvs Biotechnology peers
Price to Sales (TTM)
7.43xvs Biotechnology peers
Enterprise to Revenue
13.79xvs Biotechnology peers
Enterprise to EBITDA
-19.79xvs Biotechnology peers
Gross Margin
79.44%vs Biotechnology peers
Profit Margin
-158.32%vs Biotechnology peers
Operating Margin
-68.86%vs Biotechnology peers
Return on Assets (TTM)
-20.13%vs Biotechnology peers
Revenue (TTM)
199.71MCHF249.35M · vs all stocks (USD)
Revenue per Share (TTM)
0.8180CHFUpdated Aug 21, 2026Quarterly Revenue Growth
-26.80%vs Biotechnology peers
Gross Profit (TTM)
62.99MCHF78.64M · vs all stocks (USD)
EBITDA (TTM)
-139.12MCHF-173.70M · vs all stocks (USD)
Net Income (TTM)
-316.18MCHF-394.77M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-26.83%vs Biotechnology peers
Operating Cash Flow (TTM)
-118.15MCHF-147.51M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-35.19MCHF-43.93M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
220.58MCHFFY2025 · Dec 31, 2025Cost of Goods Sold
20.91MCHFFY2025 · Dec 31, 2025Gross Profit
199.67MCHFFY2025 · Dec 31, 2025Operating Income
-116.38MCHF-145.31M · vs all stocks (USD)
Pre-tax Income
-105.57MCHFFY2025 · Dec 31, 2025Income Tax Expense
6.12MCHFFY2025 · Dec 31, 2025Net Income
-111.70MCHFFY2025 · Dec 31, 2025EBIT
-62.93MCHFFY2025 · Dec 31, 2025EBITDA (Income Statement)
-91.80MCHFFY2025 · Dec 31, 2025Research & Development
102.21MCHFFY2025 · Dec 31, 2025Selling, General & Administrative
221.29MCHFFY2025 · Dec 31, 2025Non-operating Interest Expense
42.64MCHFFY2025 · Dec 31, 2025EPS (Basic)
-0.5200CHFFY2025 · Dec 31, 2025EPS (Diluted)
-0.5200CHFFY2025 · Dec 31, 2025Basic Shares Outstanding
214.70MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
214.70MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-111.70MCHFFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CHFFY2025 · Dec 31, 2025Operating Cash Flow
-98.81MCHFFY2025 · Dec 31, 2025Free Cash Flow
-99.28MCHFFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
88.54MCHFFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-111.70MCHFFY2025 · Dec 31, 2025Stock-based Compensation
5.70MCHFFY2025 · Dec 31, 2025Other Non-cash Items
33.32MCHFFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-7.21MCHFFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-18.92MCHFFY2025 · Dec 31, 2025Capital Expenditures
-471.00KCHFFY2025 · Dec 31, 2025Net Intangibles (CF)
-13.35MCHFFY2025 · Dec 31, 2025Sale of Investments
17.98MCHFFY2025 · Dec 31, 2025Net Investing Cash Flow
17.51MCHFFY2025 · Dec 31, 2025Long-term Debt Issuance
70.00MCHFFY2025 · Dec 31, 2025Long-term Debt Payments
-6.67MCHFFY2025 · Dec 31, 2025Net Financing Cash Flow
147.76MCHFFY2025 · Dec 31, 2025Shares Outstanding
255.04MSharesUpdated Aug 21, 2026Float Shares
148.87MSharesUpdated Aug 21, 2026% Held by Insiders
30.74%vs all stocks
% Held by Institutions
27.18%vs all stocks
Total Cash (MRQ)
88.69MCHF110.73M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.3370CHFUpdated Aug 21, 2026Total Debt (MRQ)
1.32BCHF1.65B · vs all stocks (USD)
Current Ratio (MRQ)
0.5820xvs Biotechnology peers
Book Value per Share (MRQ)
-4.54CHFUpdated Aug 21, 2026Total Assets
465.88MCHF581.67M · vs all stocks (USD)
Total Current Assets
223.81MCHFFY2025 · Dec 31, 2025Total Liabilities
1.60BCHFFY2025 · Dec 31, 2025Total Non-current Assets
242.07MCHFFY2025 · Dec 31, 2025Total Non-current Liabilities
1.44BCHFFY2025 · Dec 31, 2025Total Current Liabilities
160.86MCHFFY2025 · Dec 31, 2025Cash
87.24MCHFFY2025 · Dec 31, 2025Cash & Cash Equivalents
87.24MCHFFY2025 · Dec 31, 2025Accounts Receivable
38.72MCHFFY2025 · Dec 31, 2025Inventory
82.05MCHFFY2025 · Dec 31, 2025Accounts Payable
17.45MCHFFY2025 · Dec 31, 2025Short-term Debt
7.59MCHFFY2025 · Dec 31, 2025Other Current Liabilities
45.98MCHFFY2025 · Dec 31, 2025Long-term Debt
1.26BCHFFY2025 · Dec 31, 2025Other Non-current Liabilities
18.25MCHFFY2025 · Dec 31, 2025Common Stock (Book)
12.54MCHFFY2025 · Dec 31, 2025Retained Earnings
-3.52BCHFFY2025 · Dec 31, 2025Total Shareholders' Equity
-1.14BCHF-1.42B · vs all stocks (USD)
Treasury Stock
0.00CHFFY2025 · Dec 31, 202552-Week Low
2.44CHFUpdated Aug 21, 202652-Week High
7.56CHFUpdated Aug 21, 202652-Week Change
106.32%vs all stocks
Beta
1.66xvs all stocks
50-Day MA
6.03CHFUpdated Aug 21, 2026200-Day MA
4.33CHFUpdated Aug 21, 2026Avg 10-Day Volume
1.51MSharesUpdated Aug 21, 2026Avg 30-Day Volume
1.41MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-1.38CHFUpdated Aug 21, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 0.58×, lower than 95% of its Biotechnology peers (median 5.5×)Significant
Current ratio: 0.58Industry median: 5.50Industry P5: 0.97Peers compared: 197
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.79Profit Margin: -1.58
Financial Health
High structural barrier to entryNotable
Barrier to Entry: 9.56
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.84B, above the global median of $1.15BNotable
Market cap (USD): 1,837,111,846.619Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
OneSource Specialty Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shenzhen Edge Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Chipscreen Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Staidson (Beijing) Biopharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Novocure Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ascletis Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cohance Lifesciences Limited
Tier 1ProductionApproval-Gated PipelineRule
Mirxes Holding Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
D&D Pharmatech Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hunan Jingfeng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Tasuki Holdings Inc.
1 interpretationOperating Income Growing With Multi-Year Revenue Growth
Hebei Sinopack Electronic Co., Ltd.
1 interpretationOperating Income Growing With Multi-Year Revenue Growth
Çimsa Çimento Sanayi ve Ticaret A.Ş.
1 interpretationOperating Income Growing With Multi-Year Revenue Growth